Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Policy: Reboot the debate on genetic engineering

Arguments about whether process or product should be the focus of regulation are stalling progress, says Jennifer Kuzma.

In the United States, engineered crops now make up more than 80% of the soya bean (pictured), maize and cotton acreage. Credit: Paulo Fridman/Bloomberg via Getty

Genetic engineering (GE) has become increasingly contentious in recent years. Thousands of citizens and stakeholders in the United States are currently striving to pass mandatory food-labelling laws, ban certain GE products and create GE-free zones for growing food.

GE is the manipulation of an organism's genome through biotechnology or modern molecular techniques. It is also called genetic modification, although that term is understood by scientists to encompass older processes such as hybridization as well. With the wealth of possibilities now offered by newly developed gene-editing tools — particularly CRISPR–Cas9 — debates about the safe and appropriate uses of GE are becoming more heated. In fact, in the 20 years that I have been involved in discussions about it, oversight of GE has never seemed so much like a powder keg waiting to explode.

Nature special: CRISPR

One issue that has dominated the debate is whether the focus of regulation should be the process by which GE organisms are made or the GE products themselves (the living organisms or products derived from them).

From 1999 to 2000, I directed a US National Academy of Sciences study (see to investigate pest-resistant GE plants and their regulation. While working on that project, and in the years since, I have found that most people in favour of product-based regulation believe that there is no need to treat GE organisms differently from conventionally bred ones. Moreover, these people often claim that those who think that the process of engineering should be the focus of regulation — and thus, who want to see most or all GE products go through regulatory review before they enter the marketplace — are making arguments based on values or emotions, rather than science, to support their views.

But framing the debate around 'product versus process' is neither logical nor scientific. It is stalling productive dialogue on the development of appropriate oversight in the face of rapid advances in GE.

In a rut

The United States has had a system in place for overseeing GE products since the mid-1980s: the Coordinated Framework for Regulation of Biotechnology (CFRB). The parties involved in the development of this framework — including representatives from the Office of Science and Technology Policy (OSTP) and various federal agencies — determined that it is the final product of GE that potentially poses a risk to human health and the environment, not the process by which the product is made1.

Policy: The art of science advice to government

Product-led regulation was seen to be a science-based approach that would preclude the need for new biotechnology laws. It meant that GE organisms could be covered by existing laws for products intended to be used as pesticides, plant pests, toxic substances and so on; engineered organisms could be channelled to particular agencies — the Environmental Protection Agency (EPA), the Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) — depending on what category they fell into.

So the intended use of a product has dictated which agency has the authority to regulate it under the CFRB. Yet, in practice, it is the process of GE that has been the 'regulatory trigger' used to capture products for pre-market review.

After the CFRB was published in 1986, each agency produced documents that detailed the specific protocol for the GE-product categories under its purview. For example, the EPA described the steps that developers would need to take if they were marketing plants that have pesticide-like substances engineered into them, whereas the USDA laid out how developers should handle GE plants considered to be 'plant pests'.

These EPA and the USDA documents specified that organisms made by recombinant-DNA technologies or GE (but not their conventionally bred counterparts) must go through regulatory review before entering the marketplace.

The FDA took a different approach. It recommended through a guidance document — not a regulation — that developers of foods derived from 'new plant varieties' undergo a voluntary consultation process with the agency. This guidance did not exclude non-GE new plant varieties. In practice, however, developers of conventionally bred foods seem not to have undergone such consultations, whereas the FDA has been notified of more than 100 foods derived from GE plants (see

Science media: Centre of attention

For the EPA, the USDA and the FDA, the engineered product once again becomes the focus when the agencies actually assess the level of risk that it poses. But from a scientific standpoint, a product's traits — harmful or otherwise — depend in part on the process by which it is made. (This is especially evident from human gene-therapy trials, where new methods for delivering genes have removed the need for potentially harmful viral vectors.) And in their review procedures, the agencies recognize that the process of engineering is important. The USDA, for example, requires a “detailed description of the molecular biology of the system ... used to produce the regulated article”.

Thus, product and process issues are not distinct in regulation. Indeed, it does not make sense scientifically to try to value one approach more highly than the other.

It is impossible to be completely 'science based' in a regulatory system.

The idea that regulating products is the only 'science-based' way has been popular with regulators and developers beyond the United States. For instance, plant scientist Ingo Potrykus, who led the development of the genetically engineered vitamin-A-enriched 'golden rice' variety at the Swiss Federal Institute of Technology (ETH) in Zurich, stated in 2010 that it would be a “crime against humanity” not to change from “regulating a technology on ideological terms” to “science-based regulation, guided by considerations of the risks and benefits of the trait”2.

Yet many countries go further than the United States when it comes to process-based triggers for regulation, relying on national laws. In Brazil, a national biosafety law provides safety standards and oversight mechanisms for GE organisms; in Australia, the Gene Technology Act mandates a regulatory framework for the risk assessment and management of GE organisms.

Emerging technologies

The product-versus-process framing has reared its confusing head again in recent discussions. Gene editing involves changing DNA sequences at targeted locations, usually using site-directed nucleases (proteins that naturally cut DNA), such as CRISPR–Cas9, TALENS and zinc-finger nucleases. With these tools, genetic engineers can introduce one or a few nucleotide changes to a gene, make insertions or deletions in a gene sequence, or insert a different gene altogether, potentially from a different species. International discussions have focused on which types of gene-editing manipulation fall under regulatory definitions of GE organisms in different oversight regimes3.

Ironically, the same GE developers who once claimed that the process of GE does not matter for regulatory purposes are now arguing that changes to the engineering process justify looser regulatory scrutiny4. They contend that gene editing is a safer process than first-generation GE techniques owing to its precision and the smaller point mutations often made5.

And some US regulatory agencies are heeding these calls. Thanks to emerging methods of gene delivery and gene editing, genetic engineers no longer need to use DNA sequences from plant pests to introduce engineered genes into host plants. In part because of this change to the process by which the organisms are being made, the USDA has, for about five years, decided not to regulate about 20 engineered plants (see 'Looser scrutiny'). Several have entered the market without going through any formal regulatory review — either by the USDA or other agencies.

Credit: Source: USDA

In Europe, crop developers are anxiously waiting for the European Commission to decide how changes to GE processes should affect regulatory policy. Specifically, the commission is expected soon to deliver a verdict on whether the definition of GE organisms covers gene-edited plants in which any foreign DNA used in the engineering process has been removed through selective breeding — and which are indistinguishable from wild plants that might have acquired the same mutation naturally (see Nature 528, 319–320; 2015 ).

GE developers and some regulators have been inconsistent in their product-versus-process arguments for good reason. The dichotomy doesn't work, in practice or in theory. In fact, product-based arguments lead to one of two conclusions: if all products (GE or otherwise) are to be treated the same, then either all products — GE and conventionally bred — should be regulated, or neither should be. The first option is impractical and the second inadvisable given that some products could be harmful.

A fresh start

It is time to reset the debate. Product-versus-process arguments reflect world views about the desired level of regulation for GE organisms. These underlying viewpoints should be made explicit, and the idea that product-based regulation is the only science-based approach rejected.

In reality, it is impossible to be completely 'science based' in a regulatory system. Value judgements are embedded in all risk and safety assessments. For example, the dose–response curve for a certain food additive might be known, but such data do not by themselves tell regulators where to set an acceptable safety limit. More often, the dose–response curve is not well established, or known at all. This uncertainty leads to various interpretations of the data.

Nature special: Science advice to governments

Empirical evidence matters, but human interpretation brings meaning to that evidence, and multiple perspectives can strengthen understanding. Thus, an oversight system should focus on what concerns a diversity of stakeholders and citizens have, what evidence or risk-mitigation strategies can help to address those concerns, and what classes of GE products or processes should receive greater regulatory scrutiny. In practice, regulators and other stakeholders will need to consider a mix of product and process issues to capture product groups that are likely to be of greater concern.

Several models in the social-science literature describe how such democratic deliberation might be achieved6. And Norway's decision-making about GE organisms under its gene-technology act demonstrates how factors outside 'science-based' health or environmental harms can be incorporated into formal regulatory processes in practice. Since 2005, regulators in Norway making decisions about whether a GE organism will be released into the environment consider the results of safety reviews, and whether participants of a consultation process perceive that the organism provides a better option than alternatives and contributes to sustainable agricultural practices (see

There is a chance to start over, in the United States and elsewhere. In part because of advances in gene editing and a greater diversity of GE organisms being presented to regulators, the OSTP initiated a process in July 2015 to clarify which regulatory authority is responsible for what under the CFRB7. And just last month, the USDA published four possible scenarios for a proposed new framework for the regulation of GE crops8.

Within these efforts and others, stakeholders could do away with polarizing product-versus-process and science-versus-values framings, and help to establish a governance system that is both informed by the science and guided by the concerns and values of citizens.


  1. OSTP. Fed. Reg. 51, 23302 (1986).

  2. Potrykus, I. N. Biotechnol. 27, 466–472 (2010).

    CAS  Article  Google Scholar 

  3. Wolt, J. D., Wang, K. & Yang, B. Plant Biotechnol. J. 14, 510–518 (2015).

    Article  Google Scholar 

  4. Huang, S., Weigel, D., Beachy, R. N. & Li, J. Nature Genet. 48, 109–111 (2016).

    CAS  Article  Google Scholar 

  5. Kokotovich, A. & Kuzma, J. Bull. Sci. Technol. Soc. 34, 108–120 (2014).

    Article  Google Scholar 

  6. Ramachandran, G. et al. J. Nanopart. Res. 13, 1345–1371 (2011).

    ADS  Article  Google Scholar 

  7. Waltz, E. Nature Biotechnol. 33, 1221–1222 (2015).

    CAS  Article  Google Scholar 

  8. USDA. Fed. Reg. 81, 6225–6229 (2016).

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jennifer Kuzma.

Additional information

Tweet Facebook LinkedIn Weibo

Related links

Related links

Related links in Nature Research

India needs home-grown GM food to stop starvation 2016-Jan-27

Europe’s genetically edited plants stuck in legal limbo 2015-Dec-15

Crop conundrum 2015-Dec-15

CRISPR tweak may help gene-edited crops bypass biosafety regulation 2015-Oct-19

Gene-editing record smashed in pigs 2015-Oct-06

Nature special: CRISPR: the good, the bad and the unknown

Nature special: GM crops: promise and reality

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kuzma, J. Policy: Reboot the debate on genetic engineering. Nature 531, 165–167 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing